Celltrion seeks Australian approval for Cosentyx biosimilar

By Maekyung News Service

South Korean biopharmaceutical company Celltrion has applied for regulatory approval in Australia for BESEQUMA (secukinumab), its proposed biosimilar to Novartis’ autoimmune disease treatment Cosentyx, as it expands efforts to enter major global pharmaceutical markets.

Celltrion said Thursday that it submitted a marketing authorization application to Australia’s Therapeutic Goods Administration (TGA) for BESEQUMA.

The application covers all indications approved for the reference drug in Australia, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.

Cosentyx, developed by Swiss pharmaceutical company Novartis, works by inhibiting interleukin-17A (IL-17A), a protein involved in inflammatory responses. The drug generated $6.6 billion in global sales last year.

Celltrion said a clinical trial involving 172 healthy adults demonstrated pharmacokinetic equivalence between BESEQUMA and the reference drug, with comparable safety and immunogenicity profiles.

The company began seeking regulatory approvals for BESEQUMA in major markets earlier this year, filing applications in Canada in May, South Korea in June, and the United States and Europe in July.

The Australian submission marks another step in its strategy to expand the biosimilar’s global market presence.

Celltrion plans to increase its portfolio of marketed biosimilars from 11 to 18 by 2030.

Its development pipeline includes CT-P53, a proposed biosimilar to Roche’s Ocrevus, and CT-P52, a proposed biosimilar to Eli Lilly’s Taltz, both targeting autoimmune diseases.

In oncology, the company is developing CT-P51, a proposed biosimilar to Merck’s Keytruda, and CT-P44, a proposed biosimilar to Johnson & Johnson’s Darzalex.

“Following applications in the United States, Europe and South Korea, we are accelerating the global expansion of BESEQUMA with our latest submission in Australia,” a Celltrion official said.

“We will continue expanding regulatory filings into additional markets to strengthen the growth prospects of our biosimilar business.”

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.